Remus Pharmaceuticals H1-FY27 Financial and Operational Performance Overview
Remus Pharmaceuticals Ltd 路 Investor Presentation 路 04 Nov 2026, 5:32 pm
Remus Pharmaceuticals H1-FY27 Financial and Operational Performance Overview Remus Pharmaceuticals delivered a strong H1-FY27 consolidated performance, with operational revenue rising 53.4% YoY to INR 6,141 Mn, EBITDA increasing 11.2% YoY to INR 299 Mn, and PAT growing 14.4% YoY to INR 247 Mn. Standalone revenue and PAT grew 32.4% and 56.7% YoY to INR 621 Mn and INR 188 Mn, respectively. The company expanded its pipeline to 955+ approved products across 2,443+ global registrations and dossiers, won a 24-product tender in Bolivia, obtained Peruvian Digemid plant approval, and secured approval for Semaglutide formulations.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript 路 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet 路 29 Oct 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend/Other business. 路 03 Nov 2026
